ID   MDM2_HUMAN              Reviewed;         491 AA.
AC   Q00987; A6NL51; A8K2S6; Q13226; Q13297; Q13298; Q13299; Q13300;
AC   Q13301; Q53XW0; Q71TW9; Q8WYJ1; Q8WYJ2; Q9UGI3; Q9UMT8;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1993, sequence version 1.
DT   10-MAY-2017, entry version 222.
DE   RecName: Full=E3 ubiquitin-protein ligase Mdm2;
DE            EC=2.3.2.27;
DE   AltName: Full=Double minute 2 protein;
DE            Short=Hdm2;
DE   AltName: Full=Oncoprotein Mdm2;
DE   AltName: Full=RING-type E3 ubiquitin transferase Mdm2 {ECO:0000305};
DE   AltName: Full=p53-binding protein Mdm2;
GN   Name=MDM2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM MDM2).
RC   TISSUE=Colon;
RX   PubMed=1614537; DOI=10.1038/358080a0;
RA   Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., Vogelstein B.;
RT   "Amplification of a gene encoding a p53-associated protein in human
RT   sarcomas.";
RL   Nature 358:80-83(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS MDM2-A; MDM2-B; MDM2-C; MDM2-D
RP   AND MDM2-E).
RC   TISSUE=Ovarian carcinoma;
RX   PubMed=8705862; DOI=10.1038/nm0896-912;
RA   Sigalas I., Calvert A.H., Anderson J.J., Neal D.E., Lunec J.;
RT   "Alternatively spliced mdm2 transcripts with loss of p53 binding
RT   domain sequences: transforming ability and frequent detection in human
RT   cancer.";
RL   Nat. Med. 2:912-917(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM MDM2-ALPHA).
RX   PubMed=10597303; DOI=10.1038/sj.onc.1203182;
RA   Veldhoen N., Metcalfe S., Milner J.;
RT   "A novel exon within the mdm2 gene modulates translation initiation in
RT   vitro and disrupts the p53-binding domain of mdm2 protein.";
RL   Oncogene 18:7026-7033(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS MDM2-F AND MDM2-G), AND
RP   INTERACTION WITH TP53.
RX   PubMed=11351297; DOI=10.1002/ijc.1271;
RA   Tamborini E., Della Torre G., Lavarino C., Azzarelli A.,
RA   Carpinelli P., Pierotti M.A., Pilotti S.;
RT   "Analysis of the molecular species generated by MDM2 gene
RT   amplification in liposarcomas.";
RL   Int. J. Cancer 92:790-796(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM MDM2).
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM MDM2).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 11).
RC   TISSUE=Rhabdomyosarcoma;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-24.
RX   PubMed=7651818; DOI=10.1093/nar/23.14.2584;
RA   Zauberman A., Flusberg D., Haupt Y., Barak Y., Oren M.;
RT   "A functional p53-responsive intronic promoter is contained within the
RT   human mdm2 gene.";
RL   Nucleic Acids Res. 23:2584-2592(1995).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-9.
RX   PubMed=9270029;
RA   Landers J.E., Cassel S.L., George D.L.;
RT   "Translational enhancement of mdm2 oncogene expression in human tumor
RT   cells containing a stabilized wild-type p53 protein.";
RL   Cancer Res. 57:3562-3568(1997).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 6-491 (ISOFORM MDM2-A1).
RX   PubMed=15315825; DOI=10.1016/j.gene.2004.05.015;
RA   Liang H., Atkins H., Abdel-Fattah R., Jones S.N., Lunec J.;
RT   "Genomic organisation of the human MDM2 oncogene and relationship to
RT   its alternatively spliced mRNAs.";
RL   Gene 338:217-223(2004).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 301-481.
RX   PubMed=11087894; DOI=10.1016/S0027-5107(00)00112-3;
RA   Taubert H., Kappler M., Meye A., Bartel F., Schlott T.,
RA   Lautenschlaeger C., Bache M., Schmidt H., Wuerl P.;
RT   "A MboII polymorphism in exon 11 of the human MDM2 gene occurring in
RT   normal blood donors and in soft tissue sarcoma patients: an indication
RT   for an increased cancer susceptibility?";
RL   Mutat. Res. 456:39-44(2000).
RN   [14]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH TP53.
RX   PubMed=7689721;
RA   Olson D.C., Marechal V., Momand J., Chen J., Romocki C., Levine A.J.;
RT   "Identification and characterization of multiple mdm-2 proteins and
RT   mdm-2-p53 protein complexes.";
RL   Oncogene 8:2353-2360(1993).
RN   [15]
RP   MUTAGENESIS OF CYS-464.
RX   PubMed=9450543; DOI=10.1016/S0014-5793(97)01480-4;
RA   Honda R., Tanaka H., Yasuda H.;
RT   "Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.";
RL   FEBS Lett. 420:25-27(1997).
RN   [16]
RP   MUTAGENESIS OF CYS-441 AND CYS-478.
RX   PubMed=10608892; DOI=10.1074/jbc.274.53.38189;
RA   Sharp D.A., Kratowicz S.A., Sank M.J., George D.L.;
RT   "Stabilization of the MDM2 oncoprotein by interaction with the
RT   structurally related MDMX protein.";
RL   J. Biol. Chem. 274:38189-38196(1999).
RN   [17]
RP   PHOSPHORYLATION BY ATM.
RX   PubMed=10611322; DOI=10.1073/pnas.96.26.14973;
RA   Khosravi R., Maya R., Gottlieb T., Oren M., Shiloh Y., Shkedy D.;
RT   "Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation
RT   in response to DNA damage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:14973-14977(1999).
RN   [18]
RP   MUTAGENESIS.
RX   PubMed=10722742; DOI=10.1074/jbc.275.12.8945;
RA   Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., Weissman A.M.;
RT   "Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself
RT   and p53.";
RL   J. Biol. Chem. 275:8945-8951(2000).
RN   [19]
RP   NUCLEOLAR LOCALIZATION SIGNAL.
RX   PubMed=10707090; DOI=10.1038/35004057;
RA   Lohrum M.A.E., Ashcroft M., Kubbutat M.H.G., Vousden K.H.;
RT   "Identification of a cryptic nucleolar-localization signal in MDM2.";
RL   Nat. Cell Biol. 2:179-181(2000).
RN   [20]
RP   MUTAGENESIS OF CYS-449.
RX   PubMed=10723139; DOI=10.1038/sj.onc.1203464;
RA   Honda R., Yasuda H.;
RT   "Activity of MDM2, a ubiquitin ligase, toward p53 or itself is
RT   dependent on the RING finger domain of the ligase.";
RL   Oncogene 19:1473-1476(2000).
RN   [21]
RP   PHOSPHORYLATION AT SER-240; SER-242; SER-246; SER-260 AND SER-262.
RX   PubMed=12167711; DOI=10.1128/MCB.22.17.6170-6182.2002;
RA   Blattner C., Hay T., Meek D.W., Lane D.P.;
RT   "Hypophosphorylation of Mdm2 augments p53 stability.";
RL   Mol. Cell. Biol. 22:6170-6182(2002).
RN   [22]
RP   INTERACTION WITH HIV-1 TAT.
RX   PubMed=12883554; DOI=10.1038/ncb1023;
RA   Bres V., Kiernan R.E., Linares L.K., Chable-Bessia C., Plechakova O.,
RA   Treand C., Emiliani S., Peloponese J.-M., Jeang K.-T., Coux O.,
RA   Scheffner M., Benkirane M.;
RT   "A non-proteolytic role for ubiquitin in Tat-mediated transactivation
RT   of the HIV-1 promoter.";
RL   Nat. Cell Biol. 5:754-761(2003).
RN   [23]
RP   FUNCTION IN UBIQUITINATION OF IGF1R, AND INTERACTION WITH IGF1R.
RX   PubMed=12821780; DOI=10.1073/pnas.1431613100;
RA   Girnita L., Girnita A., Larsson O.;
RT   "Mdm2-dependent ubiquitination and degradation of the insulin-like
RT   growth factor 1 receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:8247-8252(2003).
RN   [24]
RP   INTERACTION WITH FHIT.
RX   PubMed=15313915; DOI=10.1158/0008-5472.CAN-04-0195;
RA   Nishizaki M., Sasaki J., Fang B., Atkinson E.N., Minna J.D.,
RA   Roth J.A., Ji L.;
RT   "Synergistic tumor suppression by coexpression of FHIT and p53
RT   coincides with FHIT-mediated MDM2 inactivation and p53 stabilization
RT   in human non-small cell lung cancer cells.";
RL   Cancer Res. 64:5745-5752(2004).
RN   [25]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO ACCELERATED TUMOR FORMATION.
RX   PubMed=15550242; DOI=10.1016/j.cell.2004.11.022;
RA   Bond G.L., Hu W., Bond E.E., Robins H., Lutzker S.G., Arva N.C.,
RA   Bargonetti J., Bartel F., Taubert H., Wuerl P., Onel K., Yip L.,
RA   Hwang S.J., Strong L.C., Lozano G., Levine A.J.;
RT   "A single nucleotide polymorphism in the MDM2 promoter attenuates the
RT   p53 tumor suppressor pathway and accelerates tumor formation in
RT   humans.";
RL   Cell 119:591-602(2004).
RN   [26]
RP   INTERACTION WITH DAXX.
RX   PubMed=15364927; DOI=10.1074/jbc.M406743200;
RA   Zhao L.Y., Liu J., Sidhu G.S., Niu Y., Liu Y., Wang R., Liao D.;
RT   "Negative regulation of p53 functions by Daxx and the involvement of
RT   MDM2.";
RL   J. Biol. Chem. 279:50566-50579(2004).
RN   [27]
RP   FUNCTION, INTERACTION WITH USP7, AND DEUBIQUITINATION BY USP7.
RX   PubMed=15053880; DOI=10.1016/S1097-2765(04)00157-1;
RA   Li M., Brooks C.L., Kon N., Gu W.;
RT   "A dynamic role of HAUSP in the p53-Mdm2 pathway.";
RL   Mol. Cell 13:879-886(2004).
RN   [28]
RP   FUNCTION, INTERACTION WITH PML AND RPL11, AND SUBCELLULAR LOCATION.
RX   PubMed=15195100; DOI=10.1038/ncb1147;
RA   Bernardi R., Scaglioni P.P., Bergmann S., Horn H.F., Vousden K.H.,
RA   Pandolfi P.P.;
RT   "PML regulates p53 stability by sequestering Mdm2 to the nucleolus.";
RL   Nat. Cell Biol. 6:665-672(2004).
RN   [29]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=15878855; DOI=10.1074/jbc.M501129200;
RA   Girnita L., Shenoy S.K., Sehat B., Vasilcanu R., Girnita A.,
RA   Lefkowitz R.J., Larsson O.;
RT   "{beta}-Arrestin is crucial for ubiquitination and down-regulation of
RT   the insulin-like growth factor-1 receptor by acting as adaptor for the
RT   MDM2 E3 ligase.";
RL   J. Biol. Chem. 280:24412-24419(2005).
RN   [30]
RP   INTERACTION WITH WWOX AND TP53.
RX   PubMed=16219768; DOI=10.1074/jbc.M505590200;
RA   Chang N.-S., Doherty J., Ensign A., Schultz L., Hsu L.-J., Hong Q.;
RT   "WOX1 is essential for tumor necrosis factor-, UV light-,
RT   staurosporine-, and p53-mediated cell death, and its tyrosine 33-
RT   phosphorylated form binds and stabilizes serine 46-phosphorylated
RT   p53.";
RL   J. Biol. Chem. 280:43100-43108(2005).
RN   [31]
RP   FUNCTION, AND INTERACTION WITH PSMA3.
RX   PubMed=16337594; DOI=10.1016/j.molcel.2005.10.017;
RA   Sdek P., Ying H., Chang D.L., Qiu W., Zheng H., Touitou R.,
RA   Allday M.J., Xiao Z.X.;
RT   "MDM2 promotes proteasome-dependent ubiquitin-independent degradation
RT   of retinoblastoma protein.";
RL   Mol. Cell 20:699-708(2005).
RN   [32]
RP   FUNCTION, INTERACTION WITH MTBP, AND MUTAGENESIS OF CYS-464.
RX   PubMed=15632057; DOI=10.1128/MCB.25.2.545-553.2005;
RA   Brady M., Vlatkovic N., Boyd M.T.;
RT   "Regulation of p53 and MDM2 activity by MTBP.";
RL   Mol. Cell. Biol. 25:545-553(2005).
RN   [33]
RP   INTERACTION WITH CDK5RAP3 AND CDKN2A/ARF.
RX   PubMed=16173922; DOI=10.1042/BJ20050960;
RA   Wang J., He X., Luo Y., Yarbrough W.G.;
RT   "A novel ARF-binding protein (LZAP) alters ARF regulation of HDM2.";
RL   Biochem. J. 393:489-501(2006).
RN   [34]
RP   UBIQUITINATION, INTERACTION WITH PYHIN1, AND MUTAGENESIS OF CYS-464.
RX   PubMed=16479015; DOI=10.1128/MCB.26.5.1979-1996.2006;
RA   Ding Y., Lee J.-F., Lu H., Lee M.-H., Yan D.-H.;
RT   "Interferon-inducible protein IFIXalpha1 functions as a negative
RT   regulator of HDM2.";
RL   Mol. Cell. Biol. 26:1979-1996(2006).
RN   [35]
RP   IDENTIFICATION IN A COMPLEX WITH DAXX AND USP7, INTERACTION WITH DAXX,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=16845383; DOI=10.1038/ncb1442;
RA   Tang J., Qu L.K., Zhang J., Wang W., Michaelson J.S., Degenhardt Y.Y.,
RA   El-Deiry W.S., Yang X.;
RT   "Critical role for Daxx in regulating Mdm2.";
RL   Nat. Cell Biol. 8:855-862(2006).
RN   [36]
RP   INTERACTION WITH CDKN2AIP.
RX   PubMed=17460193; DOI=10.1196/annals.1395.033;
RA   Kamrul H.M., Wadhwa R., Kaul S.C.;
RT   "CARF binds to three members (ARF, p53, and HDM2) of the p53 tumor-
RT   suppressor pathway.";
RL   Ann. N. Y. Acad. Sci. 1100:312-315(2007).
RN   [37]
RP   FUNCTION, INTERACTION WITH USP2, UBIQUITINATION, AND DEUBIQUITINATION
RP   BY USP2.
RX   PubMed=17290220; DOI=10.1038/sj.emboj.7601567;
RA   Stevenson L.F., Sparks A., Allende-Vega N., Xirodimas D.P., Lane D.P.,
RA   Saville M.K.;
RT   "The deubiquitinating enzyme USP2a regulates the p53 pathway by
RT   targeting Mdm2.";
RL   EMBO J. 26:976-986(2007).
RN   [38]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO ACCELERATED TUMOR FORMATION AND
RP   LI-FRAUMENI SYNDROME.
RX   PubMed=17003841; DOI=10.1038/sj.ejhg.5201715;
RA   Ruijs M.W., Schmidt M.K., Nevanlinna H., Tommiska J., Aittomaki K.,
RA   Pruntel R., Verhoef S., Van't Veer L.J.;
RT   "The single-nucleotide polymorphism 309 in the MDM2 gene contributes
RT   to the Li-Fraumeni syndrome and related phenotypes.";
RL   Eur. J. Hum. Genet. 15:110-114(2007).
RN   [39]
RP   INTERACTION WITH TBRG1.
RX   PubMed=17110379; DOI=10.1074/jbc.M609612200;
RA   Tompkins V.S., Hagen J., Frazier A.A., Lushnikova T., Fitzgerald M.P.,
RA   di Tommaso A.D., Ladeveze V., Domann F.E., Eischen C.M., Quelle D.E.;
RT   "A novel nuclear interactor of ARF and MDM2 (NIAM) that maintains
RT   chromosomal stability.";
RL   J. Biol. Chem. 282:1322-1333(2007).
RN   [40]
RP   INTERACTION WITH RBBP6.
RX   PubMed=17470788; DOI=10.1073/pnas.0701916104;
RA   Li L., Deng B., Xing G., Teng Y., Tian C., Cheng X., Yin X., Yang J.,
RA   Gao X., Zhu Y., Sun Q., Zhang L., Yang X., He F.;
RT   "PACT is a negative regulator of p53 and essential for cell growth and
RT   embryonic development.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:7951-7956(2007).
RN   [41]
RP   INTERACTION WITH RFFL AND RNF34, AND AUTOUBIQUITINATION.
RX   PubMed=18382127; DOI=10.4161/cc.7.5.5701;
RA   Yang W., Dicker D.T., Chen J., El-Deiry W.S.;
RT   "CARPs enhance p53 turnover by degrading 14-3-3sigma and stabilizing
RT   MDM2.";
RL   Cell Cycle 7:670-682(2008).
RN   [42]
RP   IDENTIFICATION IN A COMPLEX WITH DAXX; RASSF1 AND USP7, INTERACTION
RP   WITH RASSF1; USP7 AND DAXX, AND SUBCELLULAR LOCATION.
RX   PubMed=18566590; DOI=10.1038/emboj.2008.115;
RA   Song M.S., Song S.J., Kim S.Y., Oh H.J., Lim D.S.;
RT   "The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by
RT   disrupting the MDM2-DAXX-HAUSP complex.";
RL   EMBO J. 27:1863-1874(2008).
RN   [43]
RP   INTERACTION WITH UBXN6.
RX   PubMed=18768758; DOI=10.1091/mbc.E08-01-0067;
RA   Zweitzig D.R., Shcherbik N., Haines D.S.;
RT   "AAA ATPase p97 and adaptor UBXD1 suppress MDM2 ubiquitination and
RT   degradation and promote constitutive p53 turnover.";
RL   Mol. Biol. Cell 19:5029-5029(2008).
RN   [44]
RP   PHOSPHORYLATION AT SER-386; SER-395; SER-407; THR-419; SER-425 AND
RP   SER-429.
RX   PubMed=19816404; DOI=10.1038/emboj.2009.294;
RA   Cheng Q., Chen L., Li Z., Lane W.S., Chen J.;
RT   "ATM activates p53 by regulating MDM2 oligomerization and E3
RT   processivity.";
RL   EMBO J. 28:3857-3867(2009).
RN   [45]
RP   FUNCTION, INTERACTION WITH RYBP, AND IDENTIFICATION IN A COMPLEX WITH
RP   RYBP AND TP53.
RX   PubMed=19098711; DOI=10.1038/embor.2008.231;
RA   Chen D., Zhang J., Li M., Rayburn E.R., Wang H., Zhang R.;
RT   "RYBP stabilizes p53 by modulating MDM2.";
RL   EMBO Rep. 10:166-172(2009).
RN   [46]
RP   FUNCTION, AND INTERACTION WITH MTA1.
RX   PubMed=19837670; DOI=10.1074/jbc.M109.056499;
RA   Li D.Q., Divijendra Natha Reddy S., Pakala S.B., Wu X., Zhang Y.,
RA   Rayala S.K., Kumar R.;
RT   "MTA1 coregulator regulates p53 stability and function.";
RL   J. Biol. Chem. 284:34545-34552(2009).
RN   [47]
RP   PHOSPHORYLATION AT SER-166 BY SGK1.
RX   PubMed=19756449; DOI=10.1007/s00109-009-0525-5;
RA   Amato R., D'Antona L., Porciatti G., Agosti V., Menniti M.,
RA   Rinaldo C., Costa N., Bellacchio E., Mattarocci S., Fuiano G.,
RA   Soddu S., Paggi M.G., Lang F., Perrotti N.;
RT   "Sgk1 activates MDM2-dependent p53 degradation and affects cell
RT   proliferation, survival, and differentiation.";
RL   J. Mol. Med. 87:1221-1239(2009).
RN   [48]
RP   INTERACTION WITH HHV-8 PROTEIN VIRF4.
RX   PubMed=19369353; DOI=10.1128/JVI.02353-08;
RA   Lee H.R., Toth Z., Shin Y.C., Lee J.S., Chang H., Gu W., Oh T.K.,
RA   Kim M.H., Jung J.U.;
RT   "Kaposi's sarcoma-associated herpesvirus viral interferon regulatory
RT   factor 4 targets MDM2 to deregulate the p53 tumor suppressor
RT   pathway.";
RL   J. Virol. 83:6739-6747(2009).
RN   [49]
RP   FUNCTION, INTERACTION WITH APEX1, AND MUTAGENESIS OF CYS-464.
RX   PubMed=19219073; DOI=10.1038/onc.2009.5;
RA   Busso C.S., Iwakuma T., Izumi T.;
RT   "Ubiquitination of mammalian AP endonuclease (APE1) regulated by the
RT   p53-MDM2 signaling pathway.";
RL   Oncogene 28:1616-1625(2009).
RN   [50]
RP   IDENTIFICATION.
RX   PubMed=19139490; DOI=10.1074/mcp.M800504-MCP200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F.,
RA   Zheng Z.B., Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y.,
RA   Zhang Y.K., Deng Y.L., Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core
RT   fucosylated glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [51]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-166, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [52]
RP   FUNCTION, AND INTERACTION WITH SNAI1.
RX   PubMed=20385133; DOI=10.1016/j.febslet.2010.04.006;
RA   Lim S.O., Kim H., Jung G.;
RT   "p53 inhibits tumor cell invasion via the degradation of snail protein
RT   in hepatocellular carcinoma.";
RL   FEBS Lett. 584:2231-2236(2010).
RN   [53]
RP   FUNCTION IN DYRK2 UBIQUITINATION, AND INTERACTION WITH DYRK2.
RX   PubMed=19965871; DOI=10.1074/jbc.M109.042341;
RA   Taira N., Yamamoto H., Yamaguchi T., Miki Y., Yoshida K.;
RT   "ATM augments nuclear stabilization of DYRK2 by inhibiting MDM2 in the
RT   apoptotic response to DNA damage.";
RL   J. Biol. Chem. 285:4909-4919(2010).
RN   [54]
RP   INTERACTION WITH TRIM28 IN THE TRIM28/KAP1-ERBB4-MDM2 COMPLEX AND WITH
RP   TP53 IN THE TRIM28/KAP1-MDM2-P53/TP53 COMPLEX, FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=20858735; DOI=10.1158/1541-7786.MCR-10-0042;
RA   Gilmore-Hebert M., Ramabhadran R., Stern D.F.;
RT   "Interactions of ErbB4 and Kap1 connect the growth factor and DNA
RT   damage response pathways.";
RL   Mol. Cancer Res. 8:1388-1398(2010).
RN   [55]
RP   FUNCTION, INTERACTION WITH TP53 AND RFWD3, AND MUTAGENESIS OF CYS-464.
RX   PubMed=20173098; DOI=10.1073/pnas.0912094107;
RA   Fu X., Yucer N., Liu S., Li M., Yi P., Mu J.J., Yang T., Chu J.,
RA   Jung S.Y., O'Malley B.W., Gu W., Qin J., Wang Y.;
RT   "RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53
RT   stability in response to DNA damage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:4579-4584(2010).
RN   [56]
RP   INTERACTION WITH USP2 AND MDM4.
RX   PubMed=19838211; DOI=10.1038/onc.2009.330;
RA   Allende-Vega N., Sparks A., Lane D.P., Saville M.K.;
RT   "MdmX is a substrate for the deubiquitinating enzyme USP2a.";
RL   Oncogene 29:432-441(2010).
RN   [57]
RP   FUNCTION, AND INTERACTION WITH SNAI1 AND NOTCH1.
RX   PubMed=22128911; DOI=10.1186/1741-7007-9-83;
RA   Lim S.O., Kim H.S., Quan X., Ahn S.M., Kim H., Hsieh D., Seong J.K.,
RA   Jung G.;
RT   "Notch1 binds and induces degradation of Snail in hepatocellular
RT   carcinoma.";
RL   BMC Biol. 9:83-83(2011).
RN   [58]
RP   INTERACTION WITH TRIM13, AND UBIQUITINATION.
RX   PubMed=21333377; DOI=10.1016/j.ejcb.2010.12.001;
RA   Joo H.M., Kim J.Y., Jeong J.B., Seong K.M., Nam S.Y., Yang K.H.,
RA   Kim C.S., Kim H.S., Jeong M., An S., Jin Y.W.;
RT   "Ret finger protein 2 enhances ionizing radiation-induced apoptosis
RT   via degradation of AKT and MDM2.";
RL   Eur. J. Cell Biol. 90:420-431(2011).
RN   [59]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-166, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [60]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH PML.
RX   PubMed=22869143; DOI=10.1038/onc.2012.332;
RA   Yang Q., Liao L., Deng X., Chen R., Gray N.S., Yates J.R. III,
RA   Lee J.D.;
RT   "BMK1 is involved in the regulation of p53 through disrupting the PML-
RT   MDM2 interaction.";
RL   Oncogene 32:3156-3164(2013).
RN   [61]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 25-109 IN COMPLEX WITH P53.
RX   PubMed=8875929; DOI=10.1126/science.274.5289.948;
RA   Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J.,
RA   Levine A.J., Pavletich N.P.;
RT   "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor
RT   transactivation domain.";
RL   Science 274:948-953(1996).
RN   [62]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 224-232 IN COMPLEX WITH
RP   USP7, AND INTERACTION WITH USP7.
RX   PubMed=16402859; DOI=10.1371/journal.pbio.0040027;
RA   Hu M., Gu L., Li M., Jeffrey P.D., Gu W., Shi Y.;
RT   "Structural basis of competitive recognition of p53 and MDM2 by
RT   HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway.";
RL   PLoS Biol. 4:228-239(2006).
RN   [63]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 145-150 IN COMPLEX WITH USP7,
RP   AND INTERACTION WITH USP7.
RX   PubMed=16474402; DOI=10.1038/nsmb1067;
RA   Sheng Y., Saridakis V., Sarkari F., Duan S., Wu T., Arrowsmith C.H.,
RA   Frappier L.;
RT   "Molecular recognition of p53 and MDM2 by USP7/HAUSP.";
RL   Nat. Struct. Mol. Biol. 13:285-291(2006).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase that mediates ubiquitination
CC       of p53/TP53, leading to its degradation by the proteasome.
CC       Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and
CC       apoptosis by binding its transcriptional activation domain. Also
CC       acts as a ubiquitin ligase E3 toward itself and ARRB1. Permits the
CC       nuclear export of p53/TP53. Promotes proteasome-dependent
CC       ubiquitin-independent degradation of retinoblastoma RB1 protein.
CC       Inhibits DAXX-mediated apoptosis by inducing its ubiquitination
CC       and degradation. Component of the TRIM28/KAP1-MDM2-p53/TP53
CC       complex involved in stabilizing p53/TP53. Also component of the
CC       TRIM28/KAP1-ERBB4-MDM2 complex which links growth factor and DNA
CC       damage response pathways. Mediates ubiquitination and subsequent
CC       proteasome degradation of DYRK2 in nucleus. Ubiquitinates IGF1R
CC       and SNAI1 and promotes them to proteasomal degradation
CC       (PubMed:12821780, PubMed:15053880, PubMed:15195100,
CC       PubMed:15632057, PubMed:16337594, PubMed:17290220,
CC       PubMed:19098711, PubMed:19219073, PubMed:19837670,
CC       PubMed:19965871, PubMed:20173098, PubMed:20385133,
CC       PubMed:20858735, PubMed:22128911). Ubiquitinates DCX, leading to
CC       DCX degradation and reduction of the dendritic spine density of
CC       olfactory bulb granule cells (By similarity).
CC       {ECO:0000250|UniProtKB:P23804, ECO:0000269|PubMed:12821780,
CC       ECO:0000269|PubMed:15053880, ECO:0000269|PubMed:15195100,
CC       ECO:0000269|PubMed:15632057, ECO:0000269|PubMed:16337594,
CC       ECO:0000269|PubMed:17290220, ECO:0000269|PubMed:19098711,
CC       ECO:0000269|PubMed:19219073, ECO:0000269|PubMed:19837670,
CC       ECO:0000269|PubMed:19965871, ECO:0000269|PubMed:20173098,
CC       ECO:0000269|PubMed:20385133, ECO:0000269|PubMed:20858735,
CC       ECO:0000269|PubMed:22128911}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- SUBUNIT: Interacts with p53/TP53, TP73/p73, RBL5 and RP11. Binds
CC       specifically to RNA. Can interact with RB1, E1A-associated protein
CC       EP300 and the E2F1 transcription factor. Forms a ternary complex
CC       with p53/TP53 and WWOX. Interacts with CDKN2AIP, RFWD3, USP7,
CC       PYHIN1, UBXN6, and RBBP6. Interacts with ARRB1 and ARRB2.
CC       Interacts with PSMA3. Found in a trimeric complex with MDM2, MDM4
CC       and USP2. Interacts with USP2 (via N-terminus and C-terminus).
CC       Interacts with MDM4. Part of a complex with MDM2, DAXX, RASSF1 and
CC       USP7. Part of a complex with DAXX, MDM2 and USP7. Interacts
CC       directly with DAXX and USP7. Interacts (via C-terminus) with
CC       RASSF1 isoform A (via N-terminus); the interaction is independent
CC       of TP53. Interacts with APEX1; leading to its ubiquitination and
CC       degradation. Interacts with RYBP; this inhibits ubiquitination of
CC       TP53. Identified in a complex with RYBP and p53/TP53. Also
CC       component of the TRIM28/KAP1-MDM2-p53/TP53 complex involved in
CC       regulating p53/TP53 stabilization and activity. Binds directly
CC       both p53/TP53 and TRIM28. Component of the TRIM28/KAP1-ERBB4-MDM2
CC       complex involved in connecting growth factor responses with DNA
CC       damage. Interacts directly with both TRIM28 and ERBB4 in the
CC       complex. Interacts with DYRK2. Interacts with IGF1R. Interacts
CC       with TRIM13; the interaction ubiquitinates MDM2 leading to its
CC       proteasomal degradation. Interacts with SNAI1; this interaction
CC       promotes SNAI1 ubiquitination. Interacts with NOTCH1 (via
CC       intracellular domain). Interacts with FHIT. Interacts with RFFL
CC       and RNF34; the interaction stabilizes MDM2. Interacts with
CC       CDK5RAP3 and CDKN2A/ARF; form a ternary complex involved in
CC       regulation of p53/TP53 (PubMed:16173922). Interacts with MTA1.
CC       Interacts with AARB2. Interacts with MTBP. Interacts with PML.
CC       Interacts with RPL11. Interacts with TBRG1. Interacts with herpes
CC       virus 8 protein v-IRF4. Interacts with and ubiquitinates HIV-1
CC       Tat. {ECO:0000269|PubMed:11351297, ECO:0000269|PubMed:12821780,
CC       ECO:0000269|PubMed:12883554, ECO:0000269|PubMed:15053880,
CC       ECO:0000269|PubMed:15195100, ECO:0000269|PubMed:15313915,
CC       ECO:0000269|PubMed:15364927, ECO:0000269|PubMed:15632057,
CC       ECO:0000269|PubMed:15878855, ECO:0000269|PubMed:16173922,
CC       ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:16337594,
CC       ECO:0000269|PubMed:16402859, ECO:0000269|PubMed:16474402,
CC       ECO:0000269|PubMed:16479015, ECO:0000269|PubMed:16845383,
CC       ECO:0000269|PubMed:17110379, ECO:0000269|PubMed:17290220,
CC       ECO:0000269|PubMed:17460193, ECO:0000269|PubMed:17470788,
CC       ECO:0000269|PubMed:18382127, ECO:0000269|PubMed:18566590,
CC       ECO:0000269|PubMed:18768758, ECO:0000269|PubMed:19098711,
CC       ECO:0000269|PubMed:19219073, ECO:0000269|PubMed:19369353,
CC       ECO:0000269|PubMed:19837670, ECO:0000269|PubMed:19838211,
CC       ECO:0000269|PubMed:19965871, ECO:0000269|PubMed:20173098,
CC       ECO:0000269|PubMed:20385133, ECO:0000269|PubMed:20858735,
CC       ECO:0000269|PubMed:21333377, ECO:0000269|PubMed:22128911,
CC       ECO:0000269|PubMed:22869143, ECO:0000269|PubMed:7689721,
CC       ECO:0000269|PubMed:8875929}.
CC   -!- INTERACTION:
CC       Self; NbExp=4; IntAct=EBI-389668, EBI-389668;
CC       P31749:AKT1; NbExp=4; IntAct=EBI-389668, EBI-296087;
CC       P10275:AR; NbExp=2; IntAct=EBI-389668, EBI-608057;
CC       Q9Y297:BTRC; NbExp=9; IntAct=EBI-389668, EBI-307461;
CC       P42574:CASP3; NbExp=2; IntAct=EBI-389668, EBI-524064;
CC       Q8N726:CDKN2A; NbExp=5; IntAct=EBI-389668, EBI-625922;
CC       P48729:CSNK1A1; NbExp=3; IntAct=EBI-389668, EBI-1383726;
CC       P48729-2:CSNK1A1; NbExp=3; IntAct=EBI-389668, EBI-2040168;
CC       P48730:CSNK1D; NbExp=6; IntAct=EBI-389668, EBI-751621;
CC       Q06486:Csnk1d (xeno); NbExp=2; IntAct=EBI-389668, EBI-2910316;
CC       P49674:CSNK1E; NbExp=3; IntAct=EBI-389668, EBI-749343;
CC       Q13616:CUL1; NbExp=3; IntAct=EBI-389668, EBI-359390;
CC       Q9UER7:DAXX; NbExp=18; IntAct=EBI-389668, EBI-77321;
CC       P78352:DLG4; NbExp=3; IntAct=EBI-389668, EBI-80389;
CC       P68104:EEF1A1; NbExp=9; IntAct=EBI-389668, EBI-352162;
CC       P03372:ESR1; NbExp=2; IntAct=EBI-389668, EBI-78473;
CC       P15311:EZR; NbExp=3; IntAct=EBI-389668, EBI-1056902;
CC       Q9UKB1:FBXW11; NbExp=4; IntAct=EBI-389668, EBI-355189;
CC       Q00688:FKBP3; NbExp=2; IntAct=EBI-389668, EBI-1044081;
CC       Q62446:Fkbp3 (xeno); NbExp=4; IntAct=EBI-389668, EBI-8313562;
CC       Q9BVP2:GNL3; NbExp=3; IntAct=EBI-389668, EBI-641642;
CC       Q9NVN8:GNL3L; NbExp=8; IntAct=EBI-389668, EBI-746682;
CC       Q5T7V8:GORAB; NbExp=6; IntAct=EBI-389668, EBI-3917143;
CC       P25098:GRK2; NbExp=4; IntAct=EBI-389668, EBI-3904795;
CC       P61978:HNRNPK; NbExp=2; IntAct=EBI-389668, EBI-304185;
CC       P08069:IGF1R; NbExp=2; IntAct=EBI-389668, EBI-475981;
CC       Q8N9B5:JMY; NbExp=2; IntAct=EBI-389668, EBI-866435;
CC       P05412:JUN; NbExp=3; IntAct=EBI-389668, EBI-852823;
CC       P17535:JUND; NbExp=3; IntAct=EBI-389668, EBI-2682803;
CC       O15151:MDM4; NbExp=8; IntAct=EBI-389668, EBI-398437;
CC       P19338:NCL; NbExp=8; IntAct=EBI-389668, EBI-346967;
CC       P06748:NPM1; NbExp=5; IntAct=EBI-389668, EBI-78579;
CC       Q61937:Npm1 (xeno); NbExp=2; IntAct=EBI-389668, EBI-626362;
CC       Q15466:NR0B2; NbExp=4; IntAct=EBI-389668, EBI-3910729;
CC       Q96FW1:OTUB1; NbExp=5; IntAct=EBI-389668, EBI-1058491;
CC       P53350:PLK1; NbExp=7; IntAct=EBI-389668, EBI-476768;
CC       P29590:PML; NbExp=6; IntAct=EBI-389668, EBI-295890;
CC       P29590-5:PML; NbExp=6; IntAct=EBI-389668, EBI-304008;
CC       O15297:PPM1D; NbExp=4; IntAct=EBI-389668, EBI-1551512;
CC       Q13362:PPP2R5C; NbExp=5; IntAct=EBI-389668, EBI-1266156;
CC       P25788:PSMA3; NbExp=2; IntAct=EBI-389668, EBI-348380;
CC       P61289:PSME3; NbExp=8; IntAct=EBI-389668, EBI-355546;
CC       Q9NS23:RASSF1; NbExp=5; IntAct=EBI-389668, EBI-367363;
CC       P06400:RB1; NbExp=4; IntAct=EBI-389668, EBI-491274;
CC       P62913:RPL11; NbExp=11; IntAct=EBI-389668, EBI-354380;
CC       P62829:RPL23; NbExp=3; IntAct=EBI-389668, EBI-353303;
CC       P46777:RPL5; NbExp=5; IntAct=EBI-389668, EBI-358018;
CC       P42677:RPS27; NbExp=5; IntAct=EBI-389668, EBI-356336;
CC       Q71UM5:RPS27L; NbExp=6; IntAct=EBI-389668, EBI-355126;
CC       P23396:RPS3; NbExp=8; IntAct=EBI-389668, EBI-351193;
CC       P62081:RPS7; NbExp=15; IntAct=EBI-389668, EBI-354360;
CC       Q8N488:RYBP; NbExp=11; IntAct=EBI-389668, EBI-752324;
CC       Q92736:RYR2; NbExp=2; IntAct=EBI-389668, EBI-1170425;
CC       P23297:S100A1; NbExp=2; IntAct=EBI-389668, EBI-743686;
CC       P29034:S100A2; NbExp=2; IntAct=EBI-389668, EBI-752230;
CC       P26447:S100A4; NbExp=3; IntAct=EBI-389668, EBI-717058;
CC       P06703:S100A6; NbExp=2; IntAct=EBI-389668, EBI-352877;
CC       P04271:S100B; NbExp=2; IntAct=EBI-389668, EBI-458391;
CC       Q01105:SET; NbExp=2; IntAct=EBI-389668, EBI-1053182;
CC       P04637:TP53; NbExp=65; IntAct=EBI-389668, EBI-366083;
CC       P0CG48:UBC; NbExp=6; IntAct=EBI-389668, EBI-3390054;
CC       O75604:USP2; NbExp=4; IntAct=EBI-389668, EBI-743272;
CC       Q93009:USP7; NbExp=18; IntAct=EBI-389668, EBI-302474;
CC       Q2HR73:vIRF-4 (xeno); NbExp=2; IntAct=EBI-389668, EBI-9001898;
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleoplasm. Cytoplasm. Nucleus,
CC       nucleolus. Note=Expressed predominantly in the nucleoplasm.
CC       Interaction with ARF(P14) results in the localization of both
CC       proteins to the nucleolus. The nucleolar localization signals in
CC       both ARF(P14) and MDM2 may be necessary to allow efficient
CC       nucleolar localization of both proteins. Colocalizes with RASSF1
CC       isoform A in the nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=11;
CC       Name=Mdm2;
CC         IsoId=Q00987-1; Sequence=Displayed;
CC       Name=Mdm2-A;
CC         IsoId=Q00987-2; Sequence=VSP_003208;
CC       Name=Mdm2-A1;
CC         IsoId=Q00987-3; Sequence=VSP_003208, VSP_003214;
CC       Name=Mdm2-B;
CC         IsoId=Q00987-4; Sequence=VSP_003209;
CC       Name=Mdm2-C;
CC         IsoId=Q00987-5; Sequence=VSP_003211;
CC       Name=Mdm2-D;
CC         IsoId=Q00987-6; Sequence=VSP_003210;
CC       Name=Mdm2-E;
CC         IsoId=Q00987-7; Sequence=VSP_003212, VSP_003213;
CC       Name=Mdm2-alpha;
CC         IsoId=Q00987-8; Sequence=VSP_003207;
CC       Name=Mdm2-F;
CC         IsoId=Q00987-9; Sequence=VSP_022578;
CC         Note=Does not interact with p53/TP53.;
CC       Name=Mdm2-G;
CC         IsoId=Q00987-10; Sequence=VSP_022579;
CC       Name=11;
CC         IsoId=Q00987-11; Sequence=VSP_037997;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Isoform Mdm2-A, isoform Mdm2-B,
CC       isoform Mdm2-C, isoform Mdm2-D, isoform Mdm2-E, isoform Mdm2-F and
CC       isoform Mdm2-G are observed in a range of cancers but absent in
CC       normal tissues.
CC   -!- INDUCTION: By DNA damage.
CC   -!- DOMAIN: Region I is sufficient for binding p53 and inhibiting its
CC       G1 arrest and apoptosis functions. It also binds p73 and E2F1.
CC       Region II contains most of a central acidic region required for
CC       interaction with ribosomal protein L5 and a putative C4-type zinc
CC       finger. The RING finger domain which coordinates two molecules of
CC       zinc interacts specifically with RNA whether or not zinc is
CC       present and mediates the heterooligomerization with MDM4. It is
CC       also essential for its ubiquitin ligase E3 activity toward p53 and
CC       itself.
CC   -!- PTM: Phosphorylation on Ser-166 by SGK1 activates ubiquitination
CC       of p53/TP53. Phosphorylated at multiple sites near the RING domain
CC       by ATM upon DNA damage; this prevents oligomerization and E3
CC       ligase processivity and impedes constitutive p53/TP53 degradation.
CC       {ECO:0000269|PubMed:10611322, ECO:0000269|PubMed:12167711,
CC       ECO:0000269|PubMed:18382127, ECO:0000269|PubMed:19756449,
CC       ECO:0000269|PubMed:19816404}.
CC   -!- PTM: Autoubiquitination leads to proteasomal degradation;
CC       resulting in p53/TP53 activation it may be regulated by SFN. Also
CC       ubiquitinated by TRIM13. Deubiquitinated by USP2 leads to its
CC       accumulation and increases deubiquitination and degradation of
CC       p53/TP53. Deubiquitinated by USP7 leading to its stabilization.
CC       {ECO:0000269|PubMed:18382127}.
CC   -!- POLYMORPHISM: A polymorphism in the MDM2 promoter is associated
CC       with susceptibility to accelerated tumor formation in both
CC       hereditary and sporadic cancers [MIM:614401]. It also contributes
CC       to susceptibility to Li-Fraumeni syndrome, in patients carrying a
CC       TP53 germline mutation.
CC   -!- DISEASE: Note=Seems to be amplified in certain tumors (including
CC       soft tissue sarcomas, osteosarcomas and gliomas). A higher
CC       frequency of splice variants lacking p53 binding domain sequences
CC       was found in late-stage and high-grade ovarian and bladder
CC       carcinomas. Four of the splice variants show loss of p53 binding.
CC   -!- MISCELLANEOUS: MDM2 RING finger mutations that failed to
CC       ubiquitinate p53 in vitro did not target p53 for degradation when
CC       expressed in cells.
CC   -!- SIMILARITY: Belongs to the MDM2/MDM4 family. {ECO:0000305}.
CC   -!- CAUTION: A report observed N-glycosylation at Asn-349
CC       (PubMed:19139490). However, as the protein is not extracellular,
CC       additional evidences are required to confirm this result.
CC       {ECO:0000305|PubMed:19139490}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MDM2ID115ch12q15.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/mdm2/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Mdm2 entry;
CC       URL="https://en.wikipedia.org/wiki/Mdm2";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M92424; AAA60568.1; -; mRNA.
DR   EMBL; Z12020; CAA78055.1; -; mRNA.
DR   EMBL; U33199; AAA75514.1; -; mRNA.
DR   EMBL; U33200; AAA75515.1; -; mRNA.
DR   EMBL; U33201; AAA75516.1; -; mRNA.
DR   EMBL; U33202; AAA75517.1; -; mRNA.
DR   EMBL; U33203; AAA75518.1; -; mRNA.
DR   EMBL; AF092844; AAL40179.1; -; mRNA.
DR   EMBL; AF092845; AAL40180.1; -; mRNA.
DR   EMBL; AK290341; BAF83030.1; -; mRNA.
DR   EMBL; BT007258; AAP35922.1; -; mRNA.
DR   EMBL; AF527840; AAM78554.1; -; Genomic_DNA.
DR   EMBL; AC025423; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC009893; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; U28935; AAA82237.1; -; Genomic_DNA.
DR   EMBL; U39736; AAA82061.1; -; Genomic_DNA.
DR   EMBL; AF201370; AAF42995.1; -; mRNA.
DR   EMBL; AJ251943; CAB64448.1; -; Genomic_DNA.
DR   CCDS; CCDS61189.1; -. [Q00987-5]
DR   CCDS; CCDS8986.2; -. [Q00987-11]
DR   PIR; S24354; S24354.
DR   RefSeq; NP_001138811.1; NM_001145339.2.
DR   RefSeq; NP_001265391.1; NM_001278462.1. [Q00987-5]
DR   RefSeq; NP_002383.2; NM_002392.5. [Q00987-11]
DR   RefSeq; XP_005268929.1; XM_005268872.4. [Q00987-1]
DR   RefSeq; XP_006719462.1; XM_006719399.3. [Q00987-8]
DR   UniGene; Hs.484551; -.
DR   UniGene; Hs.733536; -.
DR   PDB; 1RV1; X-ray; 2.30 A; A/B/C=25-109.
DR   PDB; 1T4E; X-ray; 2.60 A; A/B=17-111.
DR   PDB; 1T4F; X-ray; 1.90 A; M=17-125.
DR   PDB; 1YCR; X-ray; 2.60 A; A=17-125.
DR   PDB; 1Z1M; NMR; -; A=1-118.
DR   PDB; 2AXI; X-ray; 1.40 A; A=17-125.
DR   PDB; 2C6A; NMR; -; A=290-335.
DR   PDB; 2C6B; NMR; -; A=290-335.
DR   PDB; 2F1Y; X-ray; 1.70 A; A=224-232.
DR   PDB; 2FOP; X-ray; 2.10 A; B=145-150.
DR   PDB; 2GV2; X-ray; 1.80 A; A=17-125.
DR   PDB; 2HDP; NMR; -; A/B=429-491.
DR   PDB; 2LZG; NMR; -; A=1-125.
DR   PDB; 2M86; NMR; -; B=17-125.
DR   PDB; 2MPS; NMR; -; A=3-109.
DR   PDB; 2RUH; NMR; -; A=6-102.
DR   PDB; 2VJE; X-ray; 2.20 A; A/C=428-491.
DR   PDB; 2VJF; X-ray; 2.30 A; A/C=428-491.
DR   PDB; 3EQS; X-ray; 1.65 A; A=25-109.
DR   PDB; 3G03; X-ray; 1.80 A; A/C=18-125.
DR   PDB; 3IUX; X-ray; 1.65 A; A/C=25-109.
DR   PDB; 3IWY; X-ray; 1.93 A; A/C=25-109.
DR   PDB; 3JZK; X-ray; 2.10 A; A=17-111.
DR   PDB; 3JZR; X-ray; 2.10 A; A=17-125.
DR   PDB; 3JZS; X-ray; 1.78 A; A=24-109.
DR   PDB; 3LBK; X-ray; 2.30 A; A=18-111.
DR   PDB; 3LBL; X-ray; 1.60 A; A/C/E=18-111.
DR   PDB; 3LNJ; X-ray; 2.40 A; A/C/E=25-109.
DR   PDB; 3LNZ; X-ray; 1.95 A; A/C/E/G/I/K/M/O=25-109.
DR   PDB; 3MQS; X-ray; 2.40 A; D=394-403.
DR   PDB; 3TJ2; X-ray; 2.10 A; A/C=18-111.
DR   PDB; 3TPX; X-ray; 1.80 A; A/C/E=25-109.
DR   PDB; 3TU1; X-ray; 1.60 A; A=18-125.
DR   PDB; 3V3B; X-ray; 2.00 A; A/B=24-110.
DR   PDB; 3VBG; X-ray; 2.80 A; A/B/C/D=25-109.
DR   PDB; 3VZV; X-ray; 2.80 A; A/B=25-109.
DR   PDB; 3W69; X-ray; 1.90 A; A/B=25-109.
DR   PDB; 4DIJ; X-ray; 1.90 A; A/B=17-111.
DR   PDB; 4ERE; X-ray; 1.80 A; A/B=17-111.
DR   PDB; 4ERF; X-ray; 2.00 A; A/C/E=17-111.
DR   PDB; 4HBM; X-ray; 1.90 A; A/B/C/D/E/F/G/H=6-125.
DR   PDB; 4HFZ; X-ray; 2.69 A; A/C=17-125.
DR   PDB; 4HG7; X-ray; 1.60 A; A=17-108.
DR   PDB; 4JV7; X-ray; 2.20 A; A=18-111.
DR   PDB; 4JV9; X-ray; 2.50 A; A=18-111.
DR   PDB; 4JVE; X-ray; 2.30 A; A=18-111.
DR   PDB; 4JVR; X-ray; 1.70 A; A/C/E=18-111.
DR   PDB; 4JWR; X-ray; 2.35 A; A/B/C=17-111.
DR   PDB; 4MDN; X-ray; 1.90 A; A=18-110.
DR   PDB; 4MDQ; X-ray; 2.12 A; A=25-110.
DR   PDB; 4OAS; X-ray; 1.70 A; A/C/E=17-111.
DR   PDB; 4OBA; X-ray; 1.60 A; A/B/C=17-111.
DR   PDB; 4OCC; X-ray; 1.80 A; A/C/E=17-111.
DR   PDB; 4ODE; X-ray; 1.80 A; A=6-110.
DR   PDB; 4ODF; X-ray; 2.20 A; A=6-110.
DR   PDB; 4OGN; X-ray; 1.38 A; A=6-110.
DR   PDB; 4OGT; X-ray; 1.54 A; A=6-110.
DR   PDB; 4OGV; X-ray; 2.20 A; A/B/C=17-111.
DR   PDB; 4OQ3; X-ray; 2.30 A; A/B/C/D=17-111.
DR   PDB; 4QO4; X-ray; 1.70 A; A=17-111.
DR   PDB; 4QOC; X-ray; 1.70 A; A/C/E/G/I/K=17-111.
DR   PDB; 4UD7; X-ray; 1.60 A; A/B/C/D=17-125.
DR   PDB; 4UE1; X-ray; 1.45 A; A/B/C/D=17-125.
DR   PDB; 4UMN; X-ray; 1.99 A; A/B=6-125.
DR   PDB; 4WT2; X-ray; 1.42 A; A=6-110.
DR   PDB; 4XXB; X-ray; 2.40 A; B=290-437.
DR   PDB; 4ZFI; X-ray; 2.00 A; A/B/C/D=18-113.
DR   PDB; 4ZGK; X-ray; 2.00 A; A/B=18-114.
DR   PDB; 4ZYC; X-ray; 1.95 A; A/B/C=17-111.
DR   PDB; 4ZYF; X-ray; 1.80 A; A=17-111.
DR   PDB; 4ZYI; X-ray; 1.67 A; A=17-111.
DR   PDB; 5AFG; X-ray; 1.90 A; A=17-108.
DR   PDB; 5C5A; X-ray; 1.15 A; A/B=20-111.
DR   PDB; 5HMH; X-ray; 1.79 A; A/B=21-116.
DR   PDB; 5HMI; X-ray; 1.74 A; A/B=18-116.
DR   PDB; 5HMK; X-ray; 2.17 A; A/B=17-125.
DR   PDB; 5LAV; X-ray; 1.73 A; A=19-111.
DR   PDB; 5LAW; X-ray; 1.64 A; A=18-111.
DR   PDB; 5LAY; X-ray; 2.71 A; A/B/C/D/E/F=17-111.
DR   PDB; 5LAZ; X-ray; 1.66 A; A=18-111.
DR   PDB; 5LN2; X-ray; 1.58 A; A=17-111.
DR   PDB; 5TRF; X-ray; 2.10 A; A/B/C/D/E=10-118.
DR   PDBsum; 1RV1; -.
DR   PDBsum; 1T4E; -.
DR   PDBsum; 1T4F; -.
DR   PDBsum; 1YCR; -.
DR   PDBsum; 1Z1M; -.
DR   PDBsum; 2AXI; -.
DR   PDBsum; 2C6A; -.
DR   PDBsum; 2C6B; -.
DR   PDBsum; 2F1Y; -.
DR   PDBsum; 2FOP; -.
DR   PDBsum; 2GV2; -.
DR   PDBsum; 2HDP; -.
DR   PDBsum; 2LZG; -.
DR   PDBsum; 2M86; -.
DR   PDBsum; 2MPS; -.
DR   PDBsum; 2RUH; -.
DR   PDBsum; 2VJE; -.
DR   PDBsum; 2VJF; -.
DR   PDBsum; 3EQS; -.
DR   PDBsum; 3G03; -.
DR   PDBsum; 3IUX; -.
DR   PDBsum; 3IWY; -.
DR   PDBsum; 3JZK; -.
DR   PDBsum; 3JZR; -.
DR   PDBsum; 3JZS; -.
DR   PDBsum; 3LBK; -.
DR   PDBsum; 3LBL; -.
DR   PDBsum; 3LNJ; -.
DR   PDBsum; 3LNZ; -.
DR   PDBsum; 3MQS; -.
DR   PDBsum; 3TJ2; -.
DR   PDBsum; 3TPX; -.
DR   PDBsum; 3TU1; -.
DR   PDBsum; 3V3B; -.
DR   PDBsum; 3VBG; -.
DR   PDBsum; 3VZV; -.
DR   PDBsum; 3W69; -.
DR   PDBsum; 4DIJ; -.
DR   PDBsum; 4ERE; -.
DR   PDBsum; 4ERF; -.
DR   PDBsum; 4HBM; -.
DR   PDBsum; 4HFZ; -.
DR   PDBsum; 4HG7; -.
DR   PDBsum; 4JV7; -.
DR   PDBsum; 4JV9; -.
DR   PDBsum; 4JVE; -.
DR   PDBsum; 4JVR; -.
DR   PDBsum; 4JWR; -.
DR   PDBsum; 4MDN; -.
DR   PDBsum; 4MDQ; -.
DR   PDBsum; 4OAS; -.
DR   PDBsum; 4OBA; -.
DR   PDBsum; 4OCC; -.
DR   PDBsum; 4ODE; -.
DR   PDBsum; 4ODF; -.
DR   PDBsum; 4OGN; -.
DR   PDBsum; 4OGT; -.
DR   PDBsum; 4OGV; -.
DR   PDBsum; 4OQ3; -.
DR   PDBsum; 4QO4; -.
DR   PDBsum; 4QOC; -.
DR   PDBsum; 4UD7; -.
DR   PDBsum; 4UE1; -.
DR   PDBsum; 4UMN; -.
DR   PDBsum; 4WT2; -.
DR   PDBsum; 4XXB; -.
DR   PDBsum; 4ZFI; -.
DR   PDBsum; 4ZGK; -.
DR   PDBsum; 4ZYC; -.
DR   PDBsum; 4ZYF; -.
DR   PDBsum; 4ZYI; -.
DR   PDBsum; 5AFG; -.
DR   PDBsum; 5C5A; -.
DR   PDBsum; 5HMH; -.
DR   PDBsum; 5HMI; -.
DR   PDBsum; 5HMK; -.
DR   PDBsum; 5LAV; -.
DR   PDBsum; 5LAW; -.
DR   PDBsum; 5LAY; -.
DR   PDBsum; 5LAZ; -.
DR   PDBsum; 5LN2; -.
DR   PDBsum; 5TRF; -.
DR   DisProt; DP00334; -.
DR   ProteinModelPortal; Q00987; -.
DR   SMR; Q00987; -.
DR   BioGrid; 110358; 442.
DR   DIP; DIP-392N; -.
DR   IntAct; Q00987; 182.
DR   MINT; MINT-101583; -.
DR   STRING; 9606.ENSP00000417281; -.
DR   BindingDB; Q00987; -.
DR   ChEMBL; CHEMBL5023; -.
DR   iPTMnet; Q00987; -.
DR   PhosphoSitePlus; Q00987; -.
DR   DMDM; 266516; -.
DR   EPD; Q00987; -.
DR   MaxQB; Q00987; -.
DR   PaxDb; Q00987; -.
DR   PeptideAtlas; Q00987; -.
DR   PRIDE; Q00987; -.
DR   DNASU; 4193; -.
DR   Ensembl; ENST00000258149; ENSP00000258149; ENSG00000135679. [Q00987-11]
DR   Ensembl; ENST00000299252; ENSP00000299252; ENSG00000135679. [Q00987-5]
DR   Ensembl; ENST00000360430; ENSP00000353611; ENSG00000135679. [Q00987-2]
DR   Ensembl; ENST00000393413; ENSP00000377065; ENSG00000135679. [Q00987-4]
DR   GeneID; 4193; -.
DR   KEGG; hsa:4193; -.
DR   UCSC; uc001sui.6; human. [Q00987-1]
DR   CTD; 4193; -.
DR   DisGeNET; 4193; -.
DR   GeneCards; MDM2; -.
DR   HGNC; HGNC:6973; MDM2.
DR   HPA; CAB000086; -.
DR   HPA; CAB016303; -.
DR   MalaCards; MDM2; -.
DR   MIM; 164785; gene.
DR   MIM; 614401; phenotype.
DR   neXtProt; NX_Q00987; -.
DR   OpenTargets; ENSG00000135679; -.
DR   Orphanet; 99970; Dedifferentiated liposarcoma.
DR   Orphanet; 524; Li-Fraumeni syndrome.
DR   Orphanet; 99971; Well-differentiated liposarcoma.
DR   PharmGKB; PA30718; -.
DR   eggNOG; ENOG410IGXG; Eukaryota.
DR   eggNOG; ENOG41125MP; LUCA.
DR   GeneTree; ENSGT00530000063539; -.
DR   HOVERGEN; HBG013472; -.
DR   InParanoid; Q00987; -.
DR   KO; K06643; -.
DR   OMA; GELPCKL; -.
DR   OrthoDB; EOG091G0FYK; -.
DR   PhylomeDB; Q00987; -.
DR   TreeFam; TF105306; -.
DR   BRENDA; 6.3.2.19; 2681.
DR   Reactome; R-HSA-198323; AKT phosphorylates targets in the cytosol.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-2559585; Oncogene Induced Senescence.
DR   Reactome; R-HSA-3232118; SUMOylation of transcription factors.
DR   Reactome; R-HSA-399719; Trafficking of AMPA receptors.
DR   Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-6804757; Regulation of TP53 Degradation.
DR   Reactome; R-HSA-6804760; Regulation of TP53 Activity through Methylation.
DR   Reactome; R-HSA-69541; Stabilization of p53.
DR   SignaLink; Q00987; -.
DR   SIGNOR; Q00987; -.
DR   ChiTaRS; MDM2; human.
DR   EvolutionaryTrace; Q00987; -.
DR   GeneWiki; Mdm2; -.
DR   GenomeRNAi; 4193; -.
DR   PMAP-CutDB; Q00987; -.
DR   PRO; PR:Q00987; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000135679; -.
DR   ExpressionAtlas; Q00987; baseline and differential.
DR   Genevisible; Q00987; HS.
DR   GO; GO:0005737; C:cytoplasm; IMP:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043234; C:protein complex; IDA:CAFA.
DR   GO; GO:0045202; C:synapse; IEA:Ensembl.
DR   GO; GO:0097718; F:disordered domain specific binding; IPI:CAFA.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0016874; F:ligase activity; IDA:UniProtKB.
DR   GO; GO:0061663; F:NEDD8 ligase activity; IMP:CAFA.
DR   GO; GO:0002039; F:p53 binding; IPI:UniProtKB.
DR   GO; GO:0042975; F:peroxisome proliferator activated receptor binding; IEA:Ensembl.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:CAFA.
DR   GO; GO:0097110; F:scaffold protein binding; IEA:Ensembl.
DR   GO; GO:0019789; F:SUMO transferase activity; EXP:Reactome.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:CAFA.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:1990000; P:amyloid fibril formation; IMP:CAFA.
DR   GO; GO:0003283; P:atrial septum development; IEA:Ensembl.
DR   GO; GO:0003181; P:atrioventricular valve morphogenesis; IEA:Ensembl.
DR   GO; GO:0001568; P:blood vessel development; IEA:Ensembl.
DR   GO; GO:0001974; P:blood vessel remodeling; IEA:Ensembl.
DR   GO; GO:0060411; P:cardiac septum morphogenesis; IEA:Ensembl.
DR   GO; GO:0072717; P:cellular response to actinomycin D; IDA:CAFA.
DR   GO; GO:0071312; P:cellular response to alkaloid; IEA:Ensembl.
DR   GO; GO:0071391; P:cellular response to estrogen stimulus; IEA:Ensembl.
DR   GO; GO:0071480; P:cellular response to gamma radiation; IDA:CAFA.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEP:UniProtKB.
DR   GO; GO:0071375; P:cellular response to peptide hormone stimulus; IEA:Ensembl.
DR   GO; GO:0071494; P:cellular response to UV-C; IEA:Ensembl.
DR   GO; GO:0071301; P:cellular response to vitamin B1; IEA:Ensembl.
DR   GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; IMP:UniProtKB.
DR   GO; GO:0003203; P:endocardial cushion morphogenesis; IEA:Ensembl.
DR   GO; GO:0045184; P:establishment of protein localization; IDA:BHF-UCL.
DR   GO; GO:0071157; P:negative regulation of cell cycle arrest; IDA:BHF-UCL.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0043518; P:negative regulation of DNA damage response, signal transduction by p53 class mediator; IDA:BHF-UCL.
DR   GO; GO:1902254; P:negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator; IMP:CAFA.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:0010955; P:negative regulation of protein processing; IEA:Ensembl.
DR   GO; GO:1901797; P:negative regulation of signal transduction by p53 class mediator; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0018205; P:peptidyl-lysine modification; IMP:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; TAS:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IDA:BHF-UCL.
DR   GO; GO:0046827; P:positive regulation of protein export from nucleus; IEA:Ensembl.
DR   GO; GO:1904754; P:positive regulation of vascular associated smooth muscle cell migration; IEA:Ensembl.
DR   GO; GO:1904707; P:positive regulation of vascular smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0051865; P:protein autoubiquitination; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0006461; P:protein complex assembly; IDA:UniProtKB.
DR   GO; GO:0031648; P:protein destabilization; IDA:BHF-UCL.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0034504; P:protein localization to nucleus; IDA:BHF-UCL.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0051603; P:proteolysis involved in cellular protein catabolic process; IMP:CAFA.
DR   GO; GO:0002027; P:regulation of heart rate; IEA:Ensembl.
DR   GO; GO:0042176; P:regulation of protein catabolic process; IDA:UniProtKB.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0046677; P:response to antibiotic; IEP:UniProtKB.
DR   GO; GO:0042220; P:response to cocaine; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0045472; P:response to ether; IEA:Ensembl.
DR   GO; GO:1904404; P:response to formaldehyde; IEA:Ensembl.
DR   GO; GO:0010039; P:response to iron ion; IEA:Ensembl.
DR   GO; GO:0032026; P:response to magnesium ion; IEA:Ensembl.
DR   GO; GO:0043278; P:response to morphine; IEA:Ensembl.
DR   GO; GO:0048545; P:response to steroid hormone; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:1990785; P:response to water-immersion restraint stress; IEA:Ensembl.
DR   GO; GO:0036369; P:transcription factor catabolic process; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0007089; P:traversing start control point of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0003281; P:ventricular septum development; IEA:Ensembl.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   CDD; cd00162; RING; 1.
DR   Gene3D; 1.10.245.10; -; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR028340; Mdm2.
DR   InterPro; IPR015459; MDM2_E3_ligase.
DR   InterPro; IPR016495; p53_neg-reg_MDM_2/4.
DR   InterPro; IPR003121; SWIB_MDM2_domain.
DR   InterPro; IPR001876; Znf_RanBP2.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR13844:SF33; PTHR13844:SF33; 1.
DR   Pfam; PF02201; SWIB; 1.
DR   Pfam; PF00641; zf-RanBP; 1.
DR   PIRSF; PIRSF500700; MDM2; 1.
DR   PIRSF; PIRSF006748; p53_MDM_2/4; 1.
DR   SUPFAM; SSF47592; SSF47592; 2.
DR   SUPFAM; SSF90209; SSF90209; 1.
DR   PROSITE; PS01358; ZF_RANBP2_1; 1.
DR   PROSITE; PS50199; ZF_RANBP2_2; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Host-virus interaction; Metal-binding; Nucleus; Phosphoprotein;
KW   Proto-oncogene; Reference proteome; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1    491       E3 ubiquitin-protein ligase Mdm2.
FT                                /FTId=PRO_0000157332.
FT   DOMAIN       27    107       SWIB.
FT   ZN_FING     299    328       RanBP2-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00322}.
FT   ZN_FING     438    479       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   REGION        1    110       Necessary for interaction with USP2.
FT   REGION      150    230       Interaction with PYHIN1 and necessary for
FT                                interaction with RFFL and RNF34.
FT                                {ECO:0000269|PubMed:16479015,
FT                                ECO:0000269|PubMed:18382127}.
FT   REGION      170    306       Interaction with MTBP. {ECO:0000250}.
FT   REGION      210    304       ARF-binding.
FT   REGION      223    232       Interaction with USP7.
FT   REGION      242    331       Region II.
FT   REGION      276    491       Necessary for interaction with USP2.
FT   MOTIF       179    185       Nuclear localization signal.
FT                                {ECO:0000255}.
FT   MOTIF       190    202       Nuclear export signal.
FT   MOTIF       466    473       Nucleolar localization signal.
FT                                {ECO:0000255}.
FT   COMPBIAS    210    215       Poly-Ser.
FT   COMPBIAS    243    301       Asp/Glu-rich (acidic).
FT   MOD_RES     166    166       Phosphoserine; by SGK1.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:19756449}.
FT   MOD_RES     190    190       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P23804}.
FT   MOD_RES     240    240       Phosphoserine.
FT                                {ECO:0000269|PubMed:12167711}.
FT   MOD_RES     242    242       Phosphoserine.
FT                                {ECO:0000269|PubMed:12167711}.
FT   MOD_RES     246    246       Phosphoserine.
FT                                {ECO:0000269|PubMed:12167711}.
FT   MOD_RES     260    260       Phosphoserine.
FT                                {ECO:0000269|PubMed:12167711}.
FT   MOD_RES     262    262       Phosphoserine.
FT                                {ECO:0000269|PubMed:12167711}.
FT   MOD_RES     386    386       Phosphoserine; by ATM.
FT                                {ECO:0000269|PubMed:19816404}.
FT   MOD_RES     395    395       Phosphoserine; by ATM.
FT                                {ECO:0000269|PubMed:19816404}.
FT   MOD_RES     407    407       Phosphoserine; by ATM.
FT                                {ECO:0000269|PubMed:19816404}.
FT   MOD_RES     419    419       Phosphothreonine; by ATM.
FT                                {ECO:0000269|PubMed:19816404}.
FT   MOD_RES     425    425       Phosphoserine; by ATM.
FT                                {ECO:0000269|PubMed:19816404}.
FT   MOD_RES     429    429       Phosphoserine; by ATM.
FT                                {ECO:0000269|PubMed:19816404}.
FT   VAR_SEQ       1     61       Missing (in isoform Mdm2-alpha).
FT                                {ECO:0000303|PubMed:10597303}.
FT                                /FTId=VSP_003207.
FT   VAR_SEQ       1      1       M -> MVRSRQM (in isoform 11).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_037997.
FT   VAR_SEQ      28    300       Missing (in isoform Mdm2-B).
FT                                {ECO:0000303|PubMed:8705862}.
FT                                /FTId=VSP_003209.
FT   VAR_SEQ      28    222       Missing (in isoform Mdm2-A and isoform
FT                                Mdm2-A1). {ECO:0000303|PubMed:15315825,
FT                                ECO:0000303|PubMed:8705862}.
FT                                /FTId=VSP_003208.
FT   VAR_SEQ      30    388       Missing (in isoform Mdm2-D).
FT                                {ECO:0000303|PubMed:8705862}.
FT                                /FTId=VSP_003210.
FT   VAR_SEQ      53    222       Missing (in isoform Mdm2-C).
FT                                {ECO:0000303|PubMed:8705862}.
FT                                /FTId=VSP_003211.
FT   VAR_SEQ      53     97       Missing (in isoform Mdm2-F).
FT                                {ECO:0000303|PubMed:11351297}.
FT                                /FTId=VSP_022578.
FT   VAR_SEQ      76    102       YCSNDLLGDLFGVPSFSVKEHRKIYTM -> NDCANLFPLV
FT                                DLSIRELYISNYITLGI (in isoform Mdm2-E).
FT                                {ECO:0000303|PubMed:8705862}.
FT                                /FTId=VSP_003212.
FT   VAR_SEQ     103    491       Missing (in isoform Mdm2-E).
FT                                {ECO:0000303|PubMed:8705862}.
FT                                /FTId=VSP_003213.
FT   VAR_SEQ     115    169       Missing (in isoform Mdm2-G).
FT                                {ECO:0000303|PubMed:11351297}.
FT                                /FTId=VSP_022579.
FT   VAR_SEQ     275    300       Missing (in isoform Mdm2-A1).
FT                                {ECO:0000303|PubMed:15315825}.
FT                                /FTId=VSP_003214.
FT   MUTAGEN     305    305       C->S: No loss of ubiquitin ligase E3
FT                                activity. {ECO:0000269|PubMed:10722742}.
FT   MUTAGEN     374    374       C->T: No loss of ubiquitin ligase E3
FT                                activity. {ECO:0000269|PubMed:10722742}.
FT   MUTAGEN     438    438       C->L: No loss of ubiquitin ligase E3
FT                                activity. {ECO:0000269|PubMed:10722742}.
FT   MUTAGEN     441    441       C->G: Fails to interact with MDM4.
FT                                {ECO:0000269|PubMed:10608892}.
FT   MUTAGEN     449    449       C->A: Loss of ubiquitin ligase E3
FT                                activity. {ECO:0000269|PubMed:10723139}.
FT   MUTAGEN     449    449       C->S: No substantial decrease of
FT                                ubiquitin ligase E3 activity.
FT                                {ECO:0000269|PubMed:10723139}.
FT   MUTAGEN     452    452       H->A: Loss of ubiquitin ligase E3
FT                                activity. {ECO:0000269|PubMed:10722742}.
FT   MUTAGEN     455    455       T->A: Significant decrease of ubiquitin
FT                                ligase E3 activity.
FT                                {ECO:0000269|PubMed:10722742}.
FT   MUTAGEN     457    457       H->S: Loss of ubiquitin ligase E3
FT                                activity. {ECO:0000269|PubMed:10722742}.
FT   MUTAGEN     461    461       C->S: Loss of ubiquitin ligase E3
FT                                activity. {ECO:0000269|PubMed:10722742}.
FT   MUTAGEN     464    464       C->A: Loss of ubiquitin ligase E3
FT                                activity, enhances protein stability.
FT                                Does not inhibit interaction with APEX1,
FT                                but inhibits its ubiquitin ligase E3
FT                                activity on APEX1.
FT                                {ECO:0000269|PubMed:15632057,
FT                                ECO:0000269|PubMed:16479015,
FT                                ECO:0000269|PubMed:19219073,
FT                                ECO:0000269|PubMed:20173098,
FT                                ECO:0000269|PubMed:9450543}.
FT   MUTAGEN     475    475       C->G: Loss of ubiquitin ligase E3
FT                                activity. {ECO:0000269|PubMed:10722742}.
FT   MUTAGEN     478    478       C->R: Fails to interact with MDM4.
FT                                {ECO:0000269|PubMed:10608892}.
FT   MUTAGEN     478    478       C->S: Loss of ubiquitin ligase E3
FT                                activity. {ECO:0000269|PubMed:10608892}.
FT   CONFLICT     17     17       S -> P (in Ref. 10; AAA82237).
FT                                {ECO:0000305}.
FT   STRAND        7     10       {ECO:0000244|PDB:4WT2}.
FT   STRAND       13     15       {ECO:0000244|PDB:4WT2}.
FT   STRAND       17     19       {ECO:0000244|PDB:2LZG}.
FT   HELIX        23     25       {ECO:0000244|PDB:4OGN}.
FT   STRAND       27     30       {ECO:0000244|PDB:5C5A}.
FT   HELIX        32     41       {ECO:0000244|PDB:5C5A}.
FT   STRAND       46     49       {ECO:0000244|PDB:4OBA}.
FT   HELIX        50     64       {ECO:0000244|PDB:5C5A}.
FT   STRAND       71     76       {ECO:0000244|PDB:5C5A}.
FT   STRAND       78     80       {ECO:0000244|PDB:3LBK}.
FT   HELIX        81     86       {ECO:0000244|PDB:5C5A}.
FT   STRAND       88     92       {ECO:0000244|PDB:5C5A}.
FT   HELIX        96    104       {ECO:0000244|PDB:5C5A}.
FT   STRAND      107    109       {ECO:0000244|PDB:5C5A}.
FT   STRAND      295    297       {ECO:0000244|PDB:2C6A}.
FT   HELIX       299    301       {ECO:0000244|PDB:4XXB}.
FT   TURN        306    308       {ECO:0000244|PDB:4XXB}.
FT   STRAND      314    318       {ECO:0000244|PDB:4XXB}.
FT   TURN        320    322       {ECO:0000244|PDB:4XXB}.
FT   HELIX       433    435       {ECO:0000244|PDB:2VJE}.
FT   TURN        439    441       {ECO:0000244|PDB:2VJE}.
FT   STRAND      442    444       {ECO:0000244|PDB:2VJE}.
FT   STRAND      448    452       {ECO:0000244|PDB:2VJE}.
FT   STRAND      455    460       {ECO:0000244|PDB:2VJE}.
FT   HELIX       462    470       {ECO:0000244|PDB:2VJE}.
FT   TURN        476    478       {ECO:0000244|PDB:2VJE}.
FT   STRAND      484    489       {ECO:0000244|PDB:2VJE}.
SQ   SEQUENCE   491 AA;  55233 MW;  F37CE163876BC983 CRC64;
     MCNTNMSVPT DGAVTTSQIP ASEQETLVRP KPLLLKLLKS VGAQKDTYTM KEVLFYLGQY
     IMTKRLYDEK QQHIVYCSND LLGDLFGVPS FSVKEHRKIY TMIYRNLVVV NQQESSDSGT
     SVSENRCHLE GGSDQKDLVQ ELQEEKPSSS HLVSRPSTSS RRRAISETEE NSDELSGERQ
     RKRHKSDSIS LSFDESLALC VIREICCERS SSSESTGTPS NPDLDAGVSE HSGDWLDQDS
     VSDQFSVEFE VESLDSEDYS LSEEGQELSD EDDEVYQVTV YQAGESDTDS FEEDPEISLA
     DYWKCTSCNE MNPPLPSHCN RCWALRENWL PEDKGKDKGE ISEKAKLENS TQAEEGFDVP
     DCKKTIVNDS RESCVEENDD KITQASQSQE SEDYSQPSTS SSIIYSSQED VKEFEREETQ
     DKEESVESSL PLNAIEPCVI CQGRPKNGCI VHGKTGHLMA CFTCAKKLKK RNKPCPVCRQ
     PIQMIVLTYF P
//
